1. Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine
- Author
-
Nicolas Gambier, Jean-Brice Marteau, Sophie Visvikis-Siest, Elise Jeannesson, Gérard Siest, Centre du Médicament [Nancy], Université Henri Poincaré - Nancy 1 (UHP), Service de Pharmacologie Clinique et Toxicologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Génétique épidémiologique et moléculaire des pathologies cardiovasculaires, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-Institut National de la Santé et de la Recherche Médicale (INSERM), and Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire (IGE-PCV)
- Subjects
Pharmacology ,Drug ,0303 health sciences ,Candidate gene ,business.industry ,[SDV]Life Sciences [q-bio] ,media_common.quotation_subject ,General Medicine ,Disease ,030204 cardiovascular system & hematology ,Bioinformatics ,3. Good health ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,Pharmacogenomics ,Proteome ,Molecular Medicine ,Medicine ,Personalized medicine ,business ,ComputingMilieux_MISCELLANEOUS ,Pharmacogenetics ,030304 developmental biology ,media_common - Abstract
Pharmacogenomics focuses on genes and the transcriptome and proteome. It has the potential to enhance healthcare management by improving disease diagnosis and implementing treatments adapted to each patient. Previously, pharmacogenetics of candidate genes focused on clinical research. It is now extended by using genome-wide approaches to elucidate the inherited basis of differences between individuals in their response to drugs. We summarize relevant polymorphisms of genes involved in the pharmacokinetics and pharmacodynamics of antihypertensive drugs and we give an overview of the state of pharmacogenomic research in hypertension medicine. Even if things are getting better, current pharmacogenetic studies still lack power, adequate selection of candidate genes and knowledge of their functions at the physiological level. Finally, some specific end point phenotypes (i.e., peptides or proteins related to the metabolic cycle targeted by the drug) should be integrated to propose data that are easily applicable to personalized medicine.
- Published
- 2007
- Full Text
- View/download PDF